NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $23,550,000 | -27.9% | 1,194,237 | +6.2% | 6.12% | +3.6% |
| Q1 2021 | $32,682,000 | +7.3% | 1,124,237 | +11.8% | 5.91% | -6.7% |
| Q4 2020 | $30,463,000 | +88.0% | 1,005,534 | -1.3% | 6.33% | +269.2% |
| Q3 2020 | $16,202,000 | -25.1% | 1,018,334 | -7.0% | 1.72% | -60.7% |
| Q2 2020 | $21,619,000 | +67.4% | 1,095,184 | +4.6% | 4.36% | -13.4% |
| Q1 2020 | $12,912,000 | – | 1,047,184 | – | 5.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |